Last Updated: August 15, 2026

Suppliers and packagers for XOCOVA


✉ Email this page to a colleague

« Back to Dashboard


XOCOVA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Shionogi XOCOVA ensitrelvir TABLET;ORAL 220442 NDA Shionogi Inc. 59630-711-07 1 BLISTER PACK in 1 CARTON (59630-711-07) / 7 TABLET in 1 BLISTER PACK 2026-07-02
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for XOCOVA: Which raw-material, contract-manufacturing, and fill-finish vendors can supply the product’s supply chain

Last updated: July 8, 2026

Executive summary XOCOVA suppliers break into three buckets: (1) active pharmaceutical ingredient (API) makers, (2) finished-dose and packaging manufacturers (including contract manufacturing organizations, or CMOs), and (3) logistics and regulatory-support vendors that support commercial distribution. No specific supplier roster for XOCOVA (by company name and role) is available in the provided information, so an accurate, company-specific supply-chain mapping cannot be produced.

What companies supply XOCOVA’s API and who manufactures the active ingredient

Featured answer: XOCOVA supplier identification requires mapping the drug’s registered manufacturing sites for API and for drug product; those entities are not provided.

Which API manufacturers typically appear for drugs like XOCOVA

For branded prescription products, the supply chain roster is usually populated by:

  • API manufacturers listed on FDA submissions and/or inspections
  • Drug product manufacturers listed on the label and in FDA records (NDA/BLA/ANDA supplements)
  • Secondary packaging and kit assembly vendors for multi-component products

What to extract from regulatory records to identify API suppliers

A defensible supplier list is usually derived from:

  • Drug label “manufactured for/ by” statements
  • FDA establishment listings tied to the marketing application
  • Site-specific inspection outcomes and manufacturing authorization links

Which CMOs make XOCOVA finished dosage forms and where are they located

Featured answer: Finished-dose manufacturing suppliers for XOCOVA are not stated in the provided information.

Drug product manufacturing roles that determine “supplier” status

“Supplier” can mean different roles in commercialization:

  • Tablet/capsule manufacturing (blending, granulation, compression)
  • Liquid manufacturing (mixing, filling, aseptic or terminal sterilization)
  • Packaging and labeling (secondary packaging, unit-of-use configuration)
  • Specialty manufacturing (controlled room temperature and cold-chain operations)

How contract manufacturing is typically structured

Most branded drugs rely on one or more:

  • Primary drug product CMO (DS manufacturing)
  • Final fill-finish site (DP manufacturing, if applicable)
  • Packaging site(s) for cartons and unit labels

Who provides fill-finish services for XOCOVA (bottles, blisters, syringes)

Featured answer: Fill-finish suppliers for XOCOVA are not provided.

Packaging configuration drives the vendor list

Supplier discovery depends on the marketed presentation:

  • Blister packaging usually involves blister lines and cartoning equipment at one or more sites
  • Bottled presentations require container sourcing plus label printing and packing operations
  • Injectable presentations add additional sterile processing and extractables/leachables control suppliers

How does XOCOVA procurement work: single-source vs multi-source supplier networks

Featured answer: Single-source versus multi-source network design is not determinable from the provided information.

What multi-sourcing generally looks like

When supply risk is managed, commercial networks usually include:

  • Alternate drug product sites
  • Backup packaging lines
  • Dual API sourcing with qualified change control

What creates supplier constraints

Supplier concentration increases risk when there is:

  • Highly specialized equipment (sterile filling, aseptic filling)
  • Tight impurity specs for API
  • Regulatory constraints on site changes

Which vendors support XOCOVA distribution, cold-chain logistics, and warehousing

Featured answer: Distribution logistics vendors for XOCOVA are not provided.

Typical logistics supplier categories

  • Wholesaler/distributor or 3PL network operators
  • Temperature monitoring and compliance service providers
  • Reverse logistics for returns and recalls

What evidence is required to list XOCOVA suppliers correctly

Featured answer: A correct supplier list requires linkable evidence from FDA and labeling records; none is included here.

Evidence sources used in supplier mapping

  • US FDA establishment inspection and manufacturing site data
  • FDA labeling “manufactured for” statements
  • Sponsoring NDA/ANDA manufacturing arrangements

Key Takeaways

  • A company-specific supplier roster for XOCOVA cannot be produced from the information provided.
  • Accurate supplier mapping requires FDA/label-derived manufacturing site data for API, drug product, and packaging, plus role-specific identification for fill-finish and distribution.

FAQs

  1. What information in XOCOVA’s FDA records identifies the drug product manufacturing site?
  2. How do I determine the API supplier for a brand when multiple vendors are involved in the supply chain?
  3. Do XOCOVA packaging suppliers appear on the label, or only in FDA manufacturing listings?
  4. What roles count as “suppliers” for procurement, quality agreements, and change control for XOCOVA?
  5. How can I map XOCOVA’s supply chain risk if the product uses a single fill-finish site?

References

  1. FDA. Drug Establishment Registration and Listing. US Food and Drug Administration. https://www.fda.gov/drugs/drug-establishment-registration-and-listing

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.